Lacosamide Solution
Product Images NDC 72205-034

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 72205-034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lacosamide-200ml-bottle (Lacosamide 200ml Bottle)

Label for Lacosamide Oral Solution, USP 10 mg/mL, a 200 mL oral solution prescription drug. The label includes storage instructions, dosage referencing the package insert, and manufacturer and distributor information, listing MSN Pharmaceuticals Inc. as manufacturer and Novadoz Pharmaceuticals LLC as distributor. Includes barcodes and a pharmacist advisory for dispensing the medication guide.*

FDA Label Image

Lacosamide-465ml-bottle (Lacosamide 465ml Bottle)

Label for Lacosamide Oral Solution USP 10 mg/mL, a human prescription drug oral solution. The 465 mL bottle label includes storage instructions (20°C to 25°C), discard warning after six months of opening, pharmacist dispensing guidance, manufacturer MSN Pharmaceuticals Inc., and distributor Novadoz Pharmaceuticals LLC contact information. The label is marked Rx only with barcode and NDC 72205-034-75.*

FDA Label Image

Lacosamide-fig-1 (Lacosamide Fig 1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' showing seizure reduction percentages for Lacosamide oral solution versus placebo across three studies with different dosages. The y-axis represents seizure reduction percentage ranging from 0% to 45%. Bars represent median percent reduction for placebo and multiple Lacosamide doses (200, 400, 600 mg/day) with generally higher seizure reduction in Lacosamide groups across studies, and statistical significance indicated for several comparisons.*

FDA Label Image

Lacosamide-fig-2 (Lacosamide Fig 2)

A cumulative responder rate graph depicting the proportion of patients by responder rate for Lacosamide and placebo groups in studies 2, 3, and 4. The y-axis shows responder rate from -100% (worsening) to 100% (improvement), while the x-axis represents percent of patients from 100% to 0%. The graph includes separate lines for placebo and three Lacosamide dosage groups: 200 mg/day, 400 mg/day (266 patients), and 400 mg/day (202 patients).*

FDA Label Image

Lacosamide-fig-3 (Lacosamide Fig 3)

A Kaplan-Meier survival curve graph comparing the proportion of patients over time (days) between two groups: Placebo (N=121) and Vimpat (N=118). The graph shows patient survival proportions decreasing over approximately 170 days, with Vimpat demonstrating a higher proportion of surviving patients than placebo. Additional data include risk numbers at various time points, a p-value of 0.001, hazard ratio (HR) of 0.548 indicating a 45.2% risk reduction, and a 95% confidence interval [0.381, 0.788].*

FDA Label Image

Lacosamide-structure (Lacosamide Structure)

Chemical structure of Lacosamide, illustrating its molecular components and bonds as provided in the product data for the oral solution form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.